Scorpion venom targeting breast cancer cells

Scorpion Venom: A Surprising Weapon Against Breast Cancer?

Lena Kashyap monogram
Lena Kashyap in Health & Wellness October 2026 • 4 min read.

"New research explores how scorpion venom extracts can inhibit the growth of breast cancer cells, offering a potential new avenue for treatment."


Neoplastic diseases are a significant and increasing concern in the medical field, representing a leading cause of human mortality and a serious threat to global health. Consequently, the scientific community is actively searching for effective, low-toxicity anticancer drugs and treatment strategies. In addition to conventional methods like surgery, chemotherapy, and radiotherapy, there's growing interest in biological therapies and integrative medicine.

Scorpion venom, a complex biological toxin, has garnered attention for its diverse physiological effects, including anti-epileptic, anti-cancer, analgesic, and fibrinolytic properties. Prior research suggests that scorpion venom, specifically from the Buthus matensii Karsch species, can inhibit the proliferation of human esophageal and colon cancer cell lines, reduce mitotic index, and extend survival time in mice with Ehrlich ascites carcinoma.

This article delves into a study that investigates the inhibitory effects of Buthus matensii Karsch (BmK) scorpion venom extracts on human breast cancer MCF-7 cells, aiming to elucidate the underlying mechanisms. By exploring the venom's impact on apoptosis and cell cycle progression, this research offers valuable insights into its potential as a novel anticancer agent.

AI Search Multiple angles on this topic

Venom Is Not an Approved Treatment

A report dated October 12, 2025, says Brazilian scientists found that a molecule in scorpion venom may fight breast cancer in lab tests. Experts caution that scorpion venom is not an approved treatment and that standard therapies remain the safest option. The findings are therefore early research, not an established alternative to standard care.

How Scorpion Venom Fights Cancer: Inducing Apoptosis and Disrupting the Cell Cycle

Scorpion venom targeting breast cancer cells

The study examined the impact of BmK scorpion venom extracts on two common tumor cell lines: SMMC7721 (liver cancer) and MCF-7 (breast cancer). Using the MTT assay, researchers determined that MCF-7 cells exhibited greater sensitivity to the venom. This initial finding led the team to focus on MCF-7 cells to further investigate the venom's anticancer mechanisms.

Further experiments revealed that scorpion venom extracts effectively inhibited the growth and proliferation of MCF-7 cells. This inhibition was linked to the induction of apoptosis, a process of programmed cell death, in the cancer cells. Specifically, the venom:

  • Increased the levels of Caspase-3, a key protein involved in initiating apoptosis.
  • Decreased the levels of Bcl-2, a protein that suppresses apoptosis, thereby removing a protective mechanism that cancer cells often employ.
AI Search Multiple angles on this topic

A Peptide Tested Against Triple-Negative Cells

A study of the Amazonian scorpion Brotheas amazonicus reported that its scorpine-like peptide BamazScplp1 showed strong cytolytic activity against the triple-negative MDA-MB-231 breast cancer cell line. The source describes this subtype as aggressive, with limited treatment options because it lacks estrogen, progesterone, and HER2 receptors. A separate systematic review examines scorpion venom and its bioactive proteins as potential anticancer agents, including their effects and mechanisms in breast cancer.

Evidence Has Important Limitations

A systematic review cautions that studies vary in cell-line sensitivities, assay durations, venom purification methods, and outcome measures, complicating comparisons across experiments. A separate meta-analysis of preclinical studies highlights gaps in mechanistic knowledge. These limitations mean that promising results should be interpreted cautiously and that further research is needed.

A Specific Apoptosis Result

An in vitro and in vivo study examined the anticancer potential of Hottentotta saulcyi scorpion curd venom. It reported a 62.12% apoptotic rate in MCF-7 cells exposed to a dose of 1.47 mg/L. This is a cell-line-specific result, not a reported comparison with another venom.

In addition to inducing apoptosis, the scorpion venom extracts also disrupted the cell cycle of MCF-7 cells. The venom blocked the cells from progressing from the G0/G1 phase to the S phase, essentially halting cell division. This cell cycle arrest was associated with a decrease in the levels of Cyclin D1, a protein crucial for cell cycle progression.

The Future of Scorpion Venom in Cancer Therapy

This research provides compelling evidence that BmK scorpion venom extracts possess significant anticancer activity against breast cancer cells. By inducing apoptosis and disrupting the cell cycle, the venom effectively inhibits the growth and proliferation of MCF-7 cells.

AI Search Multiple angles on this topic

Research Across Venom Sources

A study published October 19, 2024, investigated crude venom from Hottentotta saulcyi in in vitro breast carcinoma experiments and in vivo mouse models. Another study set out to test crude venom from two Buthidae scorpions, Androctonus australis and Androctonus bicolor, for its potential to inhibit breast cancer cell proliferation. These summaries describe research in experimental settings, not a demonstrated treatment for patients.

Promising Reports, Early Evidence

On June 26, 2025, ScienceAlert reported that preliminary results presented at the FAPESP Week France health conference suggested venom from the Amazon rainforest scorpion Brotheas amazonicus might help treat breast cancer. A June 18, 2025, Newsweek report said a study found that venom from an Amazonian scorpion may kill breast cancer cells, offering hope for a new treatment option. These reports point to a research direction, but describe potential rather than an established therapy.

These findings suggest that BmK scorpion venom holds promise as a potential therapeutic agent for breast cancer treatment. Further research is warranted to identify and purify the specific active components within the venom, optimize delivery methods, and evaluate its efficacy and safety in preclinical and clinical trials.

While further studies are needed, this research highlights the potential of natural compounds like scorpion venom to contribute to novel cancer therapies, offering a beacon of hope in the ongoing fight against this devastating disease.

How experimental measures compare across venom sources

  • 890 and 700 μg/mlFor Rhopalurus junceus venom, the reported IC50 was 890 μg/ml in colorectal cancer cells and 700 μg/ml in breast cancer cells.[1]
  • 0.460 and 0.699 mg/mLA subgroup analysis reported a pooled mean IC50 of 0.460 mg/mL for lung-origin cell lines, compared with 0.699 mg/mL for mammary glandular cell lines.[2]
  • 36.0 and 14.7 %In MDA-MB-231 cells, apoptosis was 36.0% and necrosis was 14.7% after 24 h of treatment with Androctonus bicolor venom.[1]
  • 40 and 50 μMThe reported IC50 values for rBmK AGAP were 40 μM for MCF-7 and 50 μM for MDA-MB-231 cells.[3]
  • 9.9, 43.6, 65.8 % inhibitionChlorotoxin treatment reduced MCF-7 cell migration by 9.9%, 43.6%, and 65.8% at 0.05, 0.5, and 5 μmol/L, respectively.[4]
  • 0, 7.7, 11.2 % inhibitionFor MDA-MB-231 cells, the corresponding migration inhibition rates were 0%, 7.7%, and 11.2%.[4]
  • 25–200 μg/mLHottentotta schach crude venom was tested at concentrations from 25 to 200 μg/mL in MCF-7 and Vero cell lines.[5]

What the cell-line results add up to

Across these experiments, venom preparations and venom-derived substances were associated with changes in cancer-cell viability, migration, and cell death. The measured effects vary with the cell line and the substance tested, so one result does not establish a general effect for all venoms.[1] [2] [3] [4] [6]

Some experiments also report changes in cellular antioxidant measures alongside mitochondrial depolarization and caspase activation; another found different antioxidant responses in MCF-7 and Vero cells. These findings describe possible cellular processes, not evidence of benefit in people.[5] [7]

How these findings sit beside other experimental work

Only a few scorpion species have been experimentally tested as anticancer agents, mainly against solid tumors. That narrow experimental base constrains how broadly findings from individual species can be generalized.[8]

Separate sources report that venom proteins can bind FasL and Bcl-2 on breast cancer cell surfaces, while a scorpine-like peptide is proposed as a starting point for research into greater tumor selectivity. These are distinct proposed mechanisms and research directions, not a single established pathway.[9] [10]

What remains unresolved about scorpion-derived agents

  • Would findings from cell experiments translate to animal models of breast cancer? The review describes such animal evidence as limited.[11]
  • What evidence exists for marketed scorpion venom products in people? The cited source says Escozine and Vidatox have not been studied in clinical trials and have not been reviewed or approved by the FDA.[10]

Sources

  1. Scorpion (Androctonus bicolor) venom exhibits cytotoxicity and induces cell cycle arrest and apoptosis in breast and colorectal cancer cell lines (pmc.ncbi.nlm.nih.gov)
  2. Therapeutic Anticancer Uses of the Active Principles of “Rhopalurus junceus” Venom (pmc.ncbi.nlm.nih.gov)
  3. Scorpion Venom Analgesic Peptide, BmK AGAP Inhibits Stemness, and Epithelial-Mesenchymal Transition by Down-Regulating PTX3 in Breast Cancer (www.frontiersin.org)
  4. Chlorotoxin targets ERα/VASP signaling pathway to combat breast cancer (pmc.ncbi.nlm.nih.gov)
  5. In-vitro Study of Hottentotta Schach Crude Venom Anticancer Effects on MCF-7 and Vero Cell Lines. (pubmed.ncbi.nlm.nih.gov)
  6. Rhopalurus junceus scorpion venom induces apoptosis in the triple negative human breast cancer cell line MDA-MB-231 (pmc.ncbi.nlm.nih.gov)
  7. Scorpion venom (Odontobuthus doriae) induces apoptosis by depolarization of mitochondria and reduces S-phase population in human breast cancer cells (MCF-7). (pubmed.ncbi.nlm.nih.gov)
  8. Voltage-Gated K+/Na+ Channels and Scorpion Venom Toxins in Cancer (pmc.ncbi.nlm.nih.gov)
  9. A novel scorpine-like peptide from the amazonian scorpion Brotheas amazonicus with cytolytic activity (www.frontiersin.org)
  10. Scorpion Venom | Memorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer Center (www.mskcc.org)
  11. Systematic Review of the Antitumor Activities and Mechanisms of Scorpion Venom on Human Breast Cancer Cells Lines (In Vitro Study) (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What type of scorpion venom was used in the study, and why?

The research focuses on the effects of Buthus matensii Karsch (BmK) scorpion venom extracts on human breast cancer MCF-7 cells. This venom was chosen for investigation because previous studies suggested its potential to inhibit the proliferation of cancer cells. The study aimed to understand the mechanisms behind the venom's anticancer effects, specifically how it induces apoptosis and disrupts the cell cycle. The implications of this research are significant because it suggests a new potential treatment for breast cancer, which is a major cause of mortality.

2

How does scorpion venom fight cancer?

Apoptosis is a process of programmed cell death that the BmK scorpion venom extracts induces in MCF-7 cells. This is a critical mechanism because cancer cells often evade this process, allowing them to grow uncontrollably. The venom increases the levels of Caspase-3, a key protein that initiates apoptosis, and decreases the levels of Bcl-2, a protein that suppresses apoptosis. By promoting apoptosis, the venom effectively eliminates the cancer cells, highlighting its potential as an anticancer agent.

3

What is the role of the cell cycle, and how does scorpion venom affect it?

The cell cycle is the process that governs cell growth and division. The BmK scorpion venom extracts disrupt the cell cycle of MCF-7 cells. The venom prevents the cells from progressing from the G0/G1 phase to the S phase, which effectively halts cell division. This cell cycle arrest is associated with a decrease in the levels of Cyclin D1, a protein required for cell cycle progression. By disrupting the cell cycle, the venom limits the proliferation of cancer cells, contributing to its anticancer effects.

4

Why did researchers focus on MCF-7 cells in the study?

The study found that MCF-7 cells exhibited greater sensitivity to the BmK scorpion venom extracts compared to SMMC7721 cells (liver cancer). This initial finding is important because it led the researchers to focus on the MCF-7 cells, allowing them to investigate the specific anticancer mechanisms of the venom in detail. This focus on MCF-7 cells is a crucial step in understanding and potentially developing a targeted treatment for breast cancer.

5

What are the implications of this research on scorpion venom?

The Buthus matensii Karsch (BmK) scorpion venom extracts show potential as a novel anticancer agent, specifically against breast cancer. By inducing apoptosis and disrupting the cell cycle, the venom effectively inhibits the growth and proliferation of MCF-7 cells. This research contributes to the search for effective, low-toxicity anticancer drugs, potentially offering a new approach to treat this prevalent disease. Further research is needed to fully explore the therapeutic potential of the BmK scorpion venom.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.